CN108686168A - A kind of ginseng and astragalus hepar kang tablet - Google Patents
A kind of ginseng and astragalus hepar kang tablet Download PDFInfo
- Publication number
- CN108686168A CN108686168A CN201810828838.8A CN201810828838A CN108686168A CN 108686168 A CN108686168 A CN 108686168A CN 201810828838 A CN201810828838 A CN 201810828838A CN 108686168 A CN108686168 A CN 108686168A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- tablet
- astragalus
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Abstract
The present invention relates to pharmaceutical technology fields, and in particular to a kind of ginseng and astragalus hepar kang tablet includes the constituent of following parts by weight:32-44 parts of Radix Codonopsis, 26-34 parts of Radix Astragali, 5-13 parts of oriental wormwood, 4-12 parts of milk thistle, 2-7 parts of ganoderma lucidum, 1-4 parts of Radix Angelicae Sinensis, 2-5 parts of giant knotweed, 1-5 parts of Radix Curcumae, 5-15 parts of matrimony vine, 6-12 parts of dandelion, 10-15 parts of Radix Glycyrrhizae, containing there are many Chinese herbal medicines of liver protecting in ginseng and astragalus hepar kang tablet of the present invention, there is good therapeutic effect for treatment oxyhepatitis, it being capable of Eradicates damp and clearing heats, regulating the function of the liver and spleen, and than existing ginseng and astragalus hepar kang tablet better efficacy, clinic tracking has not been found side effect.
Description
Technical field
The present invention relates to pharmaceutical technology fields, and in particular to a kind of ginseng and astragalus hepar kang tablet.
Background technology
Ginseng and astragalus hepar kang tablet, Chinese patent drug name.Generally by groups such as oriental wormwood, Radix Codonopsis, milk thistle, Schisandra chinensis, Radix Angelicae Sinensis, Extractum Acanthopanacis Senticosis
At.With clearing damp heat-clearing, the effect of regulating the function of the liver and spleen.For the acute hepatitis, chronic hepatitis caused by retention of damp-heat in the interior, incoordination between the liver and the spleen.
Wherein, oriental wormwood has significant hepatoprotective effect, and enriching yin and nourishing kidney, heat-clearing solution, the effect of removing jaundice, oriental wormwood is soaked hepatopathy
Certain curative effect.Oriental wormwood has complete inhibiting effect to human body tubercle bacillus, has certain inhibiting effect to certain dermatophytes.Have
The effects that significantly disappear hot dampness removing, clearing liver cholagogic, blood pressure lowering, to jaundice with damp-heat pathogen, icteric hepatitis, distending pain in the chest and hypochondrium, cholecystitis, courage
Stone disease and hypertension, vexed insomnia, rocky effect.
Radix Codonopsis is mild-natured, sweet in flavor, has the effect of tonifying middle-Jiao and Qi, strengthening spleen and tonifying lung, anticancer, decompression, anti anoxia, anti-aging, also
It can enhance human immunity, improve the activity of superoxide dismutase, the ability of free radical is eliminated in enhancing;
Milk thistle has significant protective effect, silibinin, silydianin, fine grinding for hepatic injury caused by a variety of hepatotoxic agents
Ji pavilion all has the function of stablizing cell and intracellular biological film, is the active material of a kind of anti-hepatovirus.
Schisandra chinensis have astringe the lung, puckery essence, nourshing kidney, promote the production of body fluid, receive the primary efficacies such as sweat.
Extractum Acanthopanacis Senticosi replenishes qi to invigorate the spleen, and tonifies the kidney to relieve mental strain.It is physically weak weak for the insufficiency of both the spleen and the kindey, loss of appetite, soreness of waist and knee joint,
Insomnia and dreamful sleep;Radix Astragali has enhancing body's immunity, liver protection, diuresis, anti-aging, resisting stress, decompression and wide antibacterial to make
With.
Radix Astragali can not only coronary artery dilator, improve myocardial blood supply, improve immune function, and being capable of delaying cell aging
Process.Radix Astragali is convenient, can decoction, soft extracts, infusing drugs in wine enters dish etc..
But with long-time using ginseng and astragalus hepar kang tablet discovery have some patientss occur uncomfortable in chest, dizzy, the pair of loss of appetite
Effect, research may be caused by wilsonii, and the present invention by this taste medicinal material, replace by other medicinal materials, made ginseng and astragalus hepar kang
Piece better efficacy, clinic tracking have not been found side effect.
Invention content
(One)The technical issues of solution
In view of the deficiencies of the prior art, the present invention provides a kind of ginseng and astragalus hepar kang tablets.
(Two)Technical solution
In order to achieve the above object, the present invention is achieved by the following technical programs:
A kind of ginseng and astragalus hepar kang tablet includes the constituent of following parts by weight:32-44 parts of Radix Codonopsis, 26-34 parts of Radix Astragali, oriental wormwood 5-
13 parts, 4-12 parts of milk thistle, 2-7 parts of ganoderma lucidum, 1-4 parts of Radix Angelicae Sinensis, 2-5 parts of giant knotweed, 1-5 parts of Radix Curcumae, 5-15 parts of matrimony vine, dandelion 6-
12 parts, 10-15 parts of Radix Glycyrrhizae.
Preferably, include the constituent of following parts by weight:35 parts of Radix Codonopsis, 30 parts of Radix Astragali, 11 parts of oriental wormwood, milk thistle 8
Part, 5 parts of ganoderma lucidum, 2 parts of Radix Angelicae Sinensis, 4 parts of giant knotweed, 1 part of Radix Curcumae, 8 parts of matrimony vine, 10 parts of dandelion, 14 parts of Radix Glycyrrhizae.
Preferably, include the constituent of following parts by weight:32 parts of Radix Codonopsis, 32 parts of Radix Astragali, 5 parts of oriental wormwood, milk thistle 6
Part, 3 parts of ganoderma lucidum, 4 parts of Radix Angelicae Sinensis, 4 parts of giant knotweed, 1 part of Radix Curcumae, 6 parts of matrimony vine, 8 parts of dandelion, 14 parts of Radix Glycyrrhizae.
Preferably, include the constituent of following parts by weight:40 parts of Radix Codonopsis, 30 parts of Radix Astragali, oriental wormwood 5, part, milk thistle,
12 parts, 4 parts of ganoderma lucidum, 1 part of Radix Angelicae Sinensis, 3 parts of giant knotweed, 1 part of Radix Curcumae, 8 parts of matrimony vine, 9 parts of dandelion, 10 parts of Radix Glycyrrhizae.
Preparation method is as follows:
(1)By Radix Codonopsis, Radix Astragali, oriental wormwood, milk thistle, ganoderma lucidum, Radix Angelicae Sinensis, giant knotweed, Radix Curcumae, matrimony vine, dandelion, Radix Glycyrrhizae eliminate silt and
After impurity, cleaning is spare after drying, dry, pulverize at 70-80 DEG C and is ground into fine powder, sieves with 100 mesh sieve, and is added in deionized water,
After 40-50 DEG C is impregnated 30-60min, pectase and cellulase are added, pH value 4-5 is adjusted with pH adjusting agent, is warming up to 60-
65 DEG C, restore room temperature filtering after digesting 250-300min;
(2)Filtrate is extracted with ethyl acetate three times, after combined ethyl acetate, is concentrated under reduced pressure, obtains medicinal extract, frozen drying
After obtain medicinal powder;
(3)It after medicinal powder, chitosan, carboxymethyl cellulose, dextrin mixing, is added in starch, adds water to stir to pulpous state, be placed in
Wet grain is made in high-speed mixing granulating machine, with after magnesium stearate mixing, will be added in tablet press machine after the 80-90 DEG C of drying of wet grain,
It suppresses and obtains plain piece, after film coating, sterilizing.
Preferably, Radix Codonopsis, Radix Astragali, oriental wormwood, milk thistle, ganoderma lucidum, Radix Angelicae Sinensis, giant knotweed, Radix Curcumae, matrimony vine, dandelion, Radix Glycyrrhizae it is total
The mass ratio of quality and deionized water is 1:20-30.
Preferably, the mass ratio of pectase and cellulase is 4:1.
Preferably, pH adjusting agent is any one in citric acid, acetic acid, hydrochloric acid, tartaric acid.
Preferably, the grain size of wet grain is 1-2 μm.
Preferably, ultraviolet irradiation is taken to sterilize when sterilizing, the irradiation density of ultraviolet light is 200-400W/m2.
(Three)Advantageous effect
The present invention provides a kind of ginseng and astragalus hepar kang tablets, have the advantages that:
Presently commercially available ginseng and astragalus hepar kang tablet discovery has some patientss uncomfortable in chest, dizzy, the side effect of loss of appetite occur, and research may
It is caused by wilsonii, the present invention removes this taste medicinal material, and ganoderma lucidum, giant knotweed, Radix Curcumae, matrimony vine, dandelion, Radix Glycyrrhizae is added,
Wherein, ganoderma lucidum invigorating qi for tranquilization, alleviation palpitaition, blood-enrich, giant knotweed removing dampness through diuresis and removing jaundice, clearing heat and detoxicating, removing blood stasis and analgesics is relieving cough and reducing sputum;
Radix Curcumae cures mainly blood-head tells nosebleed, jaundice:Matrimony vine nourishing the liver, nourshing kidney, moistening lung improve resistance, and dandelion, Radix Glycyrrhizae are clearing heat and detoxicating,
Blood-head can be reduced, the Chinese herbal medicine there are many liver protecting is contained in ginseng and astragalus hepar kang tablet of the present invention, is had for treatment oxyhepatitis
Good therapeutic effect, can Eradicates damp and clearing heats, regulating the function of the liver and spleen, and than existing ginseng and astragalus hepar kang tablet better efficacy, clinic tracking
It has not been found side effect.
Specific implementation mode
In order to make the object, technical scheme and advantages of the embodiment of the invention clearer, below in conjunction with the embodiment of the present invention,
Technical scheme in the embodiment of the invention is clearly and completely described, it is clear that described embodiment is the present invention one
Divide embodiment, instead of all the embodiments.Based on the embodiments of the present invention, those of ordinary skill in the art are not making
The every other embodiment obtained under the premise of creative work, shall fall within the protection scope of the present invention.
Embodiment 1:
A kind of ginseng and astragalus hepar kang tablet includes the constituent of following parts by weight:35 parts of Radix Codonopsis, 30 parts of Radix Astragali, 11 parts of oriental wormwood, fine grinding
8 parts of Ji, 5 parts of ganoderma lucidum, 2 parts of Radix Angelicae Sinensis, 4 parts of giant knotweed, 1 part of Radix Curcumae, 8 parts of matrimony vine, 10 parts of dandelion, 14 parts of Radix Glycyrrhizae.
Preparation method is as follows:
Radix Codonopsis, Radix Astragali, oriental wormwood, milk thistle, ganoderma lucidum, Radix Angelicae Sinensis, giant knotweed, Radix Curcumae, matrimony vine, dandelion, Radix Glycyrrhizae are eliminated into silt and miscellaneous
After matter, cleaning is spare after drying, dry, pulverize at 75 DEG C and is ground into fine powder, sieves with 100 mesh sieve, and 30 times of its quality of addition are gone
In ionized water, after 50 DEG C are impregnated 40min, it is 4 to add mass ratio:1 pectase and cellulase, with lemon acid for adjusting pH
Value 4-5 is warming up to 62 DEG C, restores room temperature filtering after digesting 300min;Filtrate is extracted with ethyl acetate three times, acetic acid second is merged
After ester, it is concentrated under reduced pressure, obtains medicinal extract, medicinal powder is obtained after frozen drying;By medicinal powder, chitosan, carboxymethyl cellulose, dextrin
It after mixing, is added in starch, water is added to stir to pulpous state, be placed in high-speed mixing granulating machine and the wet grain that grain size is 1 μm is made, it will
With after magnesium stearate mixing after the 85 DEG C of drying of wet grain, it is added in tablet press machine, suppresses and obtain plain piece, after film coating, ultraviolet light
The irradiation density of irradiation sterilization, ultraviolet light is 350W/m2。
Embodiment 2:
A kind of ginseng and astragalus hepar kang tablet includes the constituent of following parts by weight:32 parts of Radix Codonopsis, 32 parts of Radix Astragali, 5 parts of oriental wormwood, fine grinding
6 parts of Ji, 3 parts of ganoderma lucidum, 4 parts of Radix Angelicae Sinensis, 4 parts of giant knotweed, 1 part of Radix Curcumae, 6 parts of matrimony vine, 8 parts of dandelion, 14 parts of Radix Glycyrrhizae.
Preparation method is as follows:
Radix Codonopsis, Radix Astragali, oriental wormwood, milk thistle, ganoderma lucidum, Radix Angelicae Sinensis, giant knotweed, Radix Curcumae, matrimony vine, dandelion, Radix Glycyrrhizae are eliminated into silt and miscellaneous
After matter, cleaning is spare after drying, dry, pulverize at 70 DEG C and is ground into fine powder, sieves with 100 mesh sieve, and 30 times of its quality of addition are gone
In ionized water, after 50 DEG C are impregnated 50min, it is 4 to add mass ratio:1 pectase and cellulase, with vinegar acid for adjusting pH value
4-5 is warming up to 65 DEG C, restores room temperature filtering after digesting 250min;Filtrate is extracted with ethyl acetate three times, combined ethyl acetate
Afterwards, it is concentrated under reduced pressure, obtains medicinal extract, medicinal powder is obtained after frozen drying;Medicinal powder, chitosan, carboxymethyl cellulose, dextrin are mixed
It after even, is added in starch, water is added to stir to pulpous state, be placed in high-speed mixing granulating machine and the wet grain that grain size is 2 μm is made, it will be wet
With after magnesium stearate mixing after 90 DEG C of drying of grain, it is added in tablet press machine, suppresses and obtain plain piece, after film coating, ultraviolet light spoke
According to sterilizing, the irradiation density of ultraviolet light is 200W/m2。
Embodiment 3:
A kind of ginseng and astragalus hepar kang tablet includes the constituent of following parts by weight:40 parts of Radix Codonopsis, 30 parts of Radix Astragali, 5 parts of oriental wormwood, fine grinding
Ji, 12 parts, 4 parts of ganoderma lucidum, 1 part of Radix Angelicae Sinensis, 3 parts of giant knotweed, 1 part of Radix Curcumae, 8 parts of matrimony vine, 9 parts of dandelion, 10 parts of Radix Glycyrrhizae.
Preparation method is as follows:
Radix Codonopsis, Radix Astragali, oriental wormwood, milk thistle, ganoderma lucidum, Radix Angelicae Sinensis, giant knotweed, Radix Curcumae, matrimony vine, dandelion, Radix Glycyrrhizae are eliminated into silt and miscellaneous
After matter, cleaning is spare after drying, dry, pulverize at 70 DEG C and is ground into fine powder, sieves with 100 mesh sieve, and 30 times of its quality of addition are gone
In ionized water, after 40 DEG C are impregnated 60min, it is 4 to add mass ratio:1 pectase and cellulase, with winestone acid for adjusting pH value
4-5 is warming up to 60 DEG C, restores room temperature filtering after digesting 280min;Filtrate is extracted with ethyl acetate three times, combined ethyl acetate
Afterwards, it is concentrated under reduced pressure, obtains medicinal extract, medicinal powder is obtained after frozen drying;Medicinal powder, chitosan, carboxymethyl cellulose, dextrin are mixed
It after even, is added in starch, water is added to stir to pulpous state, be placed in high-speed mixing granulating machine and the wet grain that grain size is 1.5 μm is made, it will
With after magnesium stearate mixing after the 80 DEG C of drying of wet grain, it is added in tablet press machine, suppresses and obtain plain piece, after film coating, ultraviolet light
The irradiation density of irradiation sterilization, ultraviolet light is 300W/m2。
Embodiment 4:
A kind of ginseng and astragalus hepar kang tablet includes the constituent of following parts by weight:32 parts of Radix Codonopsis, 26 parts of Radix Astragali, 5 parts of oriental wormwood, fine grinding
4 parts of Ji, 2 parts of ganoderma lucidum, 1 part of Radix Angelicae Sinensis, 2 parts of giant knotweed, 1 part of Radix Curcumae, 5 parts of matrimony vine, 6 parts of dandelion, 10 parts of Radix Glycyrrhizae.
Preparation method is as follows:
Radix Codonopsis, Radix Astragali, oriental wormwood, milk thistle, ganoderma lucidum, Radix Angelicae Sinensis, giant knotweed, Radix Curcumae, matrimony vine, dandelion, Radix Glycyrrhizae are eliminated into silt and miscellaneous
After matter, cleaning is spare after drying, dry, pulverize at 70 DEG C and is ground into fine powder, sieves with 100 mesh sieve, and 20 times of its quality of addition are gone
In ionized water, after 40 DEG C are impregnated 30min, it is 4 to add mass ratio:1 pectase and cellulase, with winestone acid for adjusting pH value
4-5 is warming up to 60 DEG C, restores room temperature filtering after digesting 250min;Filtrate is extracted with ethyl acetate three times, combined ethyl acetate
Afterwards, it is concentrated under reduced pressure, obtains medicinal extract, medicinal powder is obtained after frozen drying;Medicinal powder, chitosan, carboxymethyl cellulose, dextrin are mixed
It after even, is added in starch, water is added to stir to pulpous state, be placed in high-speed mixing granulating machine and the wet grain that grain size is 1 μm is made, it will be wet
With after magnesium stearate mixing after 80 DEG C of drying of grain, it is added in tablet press machine, suppresses and obtain plain piece, after film coating, ultraviolet light spoke
According to sterilizing, the irradiation density of ultraviolet light is 200W/m2。
Embodiment 5:
A kind of ginseng and astragalus hepar kang tablet includes the constituent of following parts by weight:44 parts of Radix Codonopsis, 34 parts of Radix Astragali, 13 parts of oriental wormwood, fine grinding
12 parts of Ji, 7 parts of ganoderma lucidum, 4 parts of Radix Angelicae Sinensis, 5 parts of giant knotweed, 5 parts of Radix Curcumae, 15 parts of matrimony vine, 12 parts of dandelion, 15 parts of Radix Glycyrrhizae.
Preparation method is as follows:
Radix Codonopsis, Radix Astragali, oriental wormwood, milk thistle, ganoderma lucidum, Radix Angelicae Sinensis, giant knotweed, Radix Curcumae, matrimony vine, dandelion, Radix Glycyrrhizae are eliminated into silt and miscellaneous
After matter, cleaning is spare after drying, dry, pulverize at 80 DEG C and is ground into fine powder, sieves with 100 mesh sieve, and 30 times of its quality of addition are gone
In ionized water, after 50 DEG C are impregnated 60min, it is 4 to add mass ratio:1 pectase and cellulase, with salt acid for adjusting pH value
4-5 is warming up to 65 DEG C, restores room temperature filtering after digesting 300min;Filtrate is extracted with ethyl acetate three times, combined ethyl acetate
Afterwards, it is concentrated under reduced pressure, obtains medicinal extract, medicinal powder is obtained after frozen drying;Medicinal powder, chitosan, carboxymethyl cellulose, dextrin are mixed
It after even, is added in starch, water is added to stir to pulpous state, be placed in high-speed mixing granulating machine and the wet grain that grain size is 2 μm is made, it will be wet
With after magnesium stearate mixing after 90 DEG C of drying of grain, it is added in tablet press machine, suppresses and obtain plain piece, after film coating, ultraviolet light spoke
According to sterilizing, the irradiation density of ultraviolet light is 400W/m2。
Clinical test:
Selection is diagnosed as the patient 90 of oxyhepatitis, is randomly divided into treatment group 30 and control group I 30, control group II 30
Example;Wherein treatment group, the age, the course of disease was between the 1-5 months between 18-58 Sui;Control group I, age are sick between 20-55 Sui
Journey is between the 1-4 months, control group II, and the age, the course of disease was in the 1-5 months between 21-60 Sui.Three groups of patient ages, course of disease difference without
Conspicuousness(P > 0.05).
Treatment group gives the treatment of the ginseng and astragalus hepar kang tablet prepared by the embodiment of the present invention 1, three times a day, each one;Control group I
Vidarabine Monophosphate 1mg joint thymic peptide 0.5mg, 3 times/d treatments are given, control group II gives commercially available ginseng and astragalus hepar kang tablet treatment, often
Day three times, each one.
Three groups are 15d as a treatment course, and clinical test comparing result is as shown in table 1.
Table 1:
| Treatment group | Control group I | Control group II | |
| It cures(%) | 44.5 | 33.6 | 26.4 |
| It is effective(%) | 23.1 | 17.1 | 20.5 |
| Effectively(%) | 3.2 | 5.6 | 2.8 |
| In vain(%) | 29.2 | 44.7 | 50.3 |
| It is total effective(%) | 70.8 | 56.3 | 49.7 |
| There is side effect(%) | 0 | 13.8 | 22.6 |
Case introduction:
Mrs Ding, 20 years old, arthralgia, fash, weak, anorexia detested greasy, Nausea and vomiting, abdominal pain, diarrhea 7 days;Urinate color
Deep yellow, pain in the hepatic region, hepatomegaly, matter are softer, have tenderness and kowtow pain, continue 6 days.After 2 courses for the treatment of of drug made of the present invention on probation, disease
Shape disappears, and gets well.
Mr. Wang, 36 years old, for patient's fever in 2 weeks up to 38 DEG C, anorexia, nausea, right upper quadrant of the abdomen were uncomfortable, vomit once in a while, 1 week
There is xanthochromia in preceding skin, and urine color is more yellow, no skin itching, and stool is normal, and sleep is slightly worse, and weight is without significant change;Trial edition is sent out
After 3 courses for the treatment of of drug made of bright, symptom disappears.
It should be noted that herein, relational terms such as first and second and the like are used merely to a reality
Body or operation are distinguished with another entity or operation, are deposited without necessarily requiring or implying between these entities or operation
In any actual relationship or order or sequence.Moreover, the terms "include", "comprise" or its any other variant are intended to
Non-exclusive inclusion, so that the process, method, article or equipment including a series of elements is not only wanted including those
Element, but also include other elements that are not explicitly listed, or further include for this process, method, article or equipment
Intrinsic element.In the absence of more restrictions, the element limited by sentence "including a ...", it is not excluded that
There is also other identical elements in process, method, article or equipment including the element.
The above embodiments are merely illustrative of the technical solutions of the present invention, rather than its limitations;Although with reference to the foregoing embodiments
Invention is explained in detail, it will be understood by those of ordinary skill in the art that:It still can be to aforementioned each implementation
Technical solution recorded in example is modified or equivalent replacement of some of the technical features;And these modification or
It replaces, the spirit and scope for various embodiments of the present invention technical solution that it does not separate the essence of the corresponding technical solution.
Claims (10)
1. a kind of ginseng and astragalus hepar kang tablet, which is characterized in that include the constituent of following parts by weight:32-44 parts of Radix Codonopsis, Radix Astragali
26-34 parts, 5-13 parts of oriental wormwood, 4-12 parts of milk thistle, 2-7 parts of ganoderma lucidum, 1-4 parts of Radix Angelicae Sinensis, 2-5 parts of giant knotweed, 1-5 parts of Radix Curcumae, matrimony vine
5-15 parts, 6-12 parts of dandelion, 10-15 parts of Radix Glycyrrhizae.
2. ginseng and astragalus hepar kang tablet as described in claim 1, which is characterized in that include the constituent of following parts by weight:Radix Codonopsis
35 parts, 30 parts of Radix Astragali, 11 parts of oriental wormwood, 8 parts of milk thistle, 5 parts of ganoderma lucidum, 2 parts of Radix Angelicae Sinensis, 4 parts of giant knotweed, 1 part of Radix Curcumae, 8 parts of matrimony vine, Pu Gong
10 parts of English, 14 parts of Radix Glycyrrhizae.
3. ginseng and astragalus hepar kang tablet as described in claim 1, which is characterized in that include the constituent of following parts by weight:Radix Codonopsis
32 parts, 32 parts of Radix Astragali, 5 parts of oriental wormwood, 6 parts of milk thistle, 3 parts of ganoderma lucidum, 4 parts of Radix Angelicae Sinensis, 4 parts of giant knotweed, 1 part of Radix Curcumae, 6 parts of matrimony vine, Pu Gong
8 parts of English, 14 parts of Radix Glycyrrhizae.
4. ginseng and astragalus hepar kang tablet as described in claim 1, which is characterized in that include the constituent of following parts by weight:Radix Codonopsis
40 parts, 30 parts of Radix Astragali, 5 parts of oriental wormwood, milk thistle, 12 parts, 4 parts of ganoderma lucidum, 1 part of Radix Angelicae Sinensis, 3 parts of giant knotweed, 1 part of Radix Curcumae, 8 parts of matrimony vine, Pu
9 parts of public English, 10 parts of Radix Glycyrrhizae.
5. ginseng and astragalus hepar kang tablet as described in any one in claim 1-5, which is characterized in that preparation method is as follows:
(1)By Radix Codonopsis, Radix Astragali, oriental wormwood, milk thistle, ganoderma lucidum, Radix Angelicae Sinensis, giant knotweed, Radix Curcumae, matrimony vine, dandelion, Radix Glycyrrhizae eliminate silt and
After impurity, cleaning is spare after drying, dry, pulverize at 70-80 DEG C and is ground into fine powder, sieves with 100 mesh sieve, and is added in deionized water,
After 40-50 DEG C is impregnated 30-60min, pectase and cellulase are added, pH value 4-5 is adjusted with pH adjusting agent, is warming up to 60-
65 DEG C, restore room temperature filtering after digesting 250-300min;
(2)Filtrate is extracted with ethyl acetate three times, after combined ethyl acetate, is concentrated under reduced pressure, obtains medicinal extract, frozen drying
After obtain medicinal powder;
(3)It after medicinal powder, chitosan, carboxymethyl cellulose, dextrin mixing, is added in starch, adds water to stir to pulpous state, be placed in
Wet grain is made in high-speed mixing granulating machine, with after magnesium stearate mixing, will be added in tablet press machine after the 80-90 DEG C of drying of wet grain,
It suppresses and obtains plain piece, after film coating, sterilizing.
6. ginseng and astragalus hepar kang tablet as claimed in claim 5, which is characterized in that Radix Codonopsis, Radix Astragali, oriental wormwood, milk thistle, ganoderma lucidum, Radix Angelicae Sinensis,
Giant knotweed, Radix Curcumae, matrimony vine, dandelion, the gross mass of Radix Glycyrrhizae and deionized water mass ratio be 1:20-30.
7. ginseng and astragalus hepar kang tablet as claimed in claim 5, which is characterized in that the mass ratio of pectase and cellulase is 4:1.
8. ginseng and astragalus hepar kang tablet as claimed in claim 5, which is characterized in that pH adjusting agent is citric acid, acetic acid, hydrochloric acid, winestone
Any one in acid.
9. ginseng and astragalus hepar kang tablet as claimed in claim 5, which is characterized in that the grain size of wet grain is 1-2 μm.
10. ginseng and astragalus hepar kang tablet as claimed in claim 5, which is characterized in that take ultraviolet irradiation to sterilize when sterilizing, ultraviolet light
Irradiation density be 200-400W/m2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810828838.8A CN108686168A (en) | 2018-07-25 | 2018-07-25 | A kind of ginseng and astragalus hepar kang tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810828838.8A CN108686168A (en) | 2018-07-25 | 2018-07-25 | A kind of ginseng and astragalus hepar kang tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108686168A true CN108686168A (en) | 2018-10-23 |
Family
ID=63851758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810828838.8A Pending CN108686168A (en) | 2018-07-25 | 2018-07-25 | A kind of ginseng and astragalus hepar kang tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108686168A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1233487A (en) * | 1998-04-24 | 1999-11-03 | 汪东平 | Medicine for treating hepatitis B |
| CN1895619A (en) * | 2005-07-14 | 2007-01-17 | 兰州太宝制药有限公司 | Chinese-medicinal composition for preventing and treating liver disease and its preparation |
| KR20070097234A (en) * | 2006-03-29 | 2007-10-04 | 장병간 | Lactic acid fermentation composition using edible herbs and the preparation method of thereof |
| CN104147270A (en) * | 2014-08-28 | 2014-11-19 | 广西梧州三鹤药业有限公司 | Traditional Chinese medicine for treating acute hepatitis |
-
2018
- 2018-07-25 CN CN201810828838.8A patent/CN108686168A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1233487A (en) * | 1998-04-24 | 1999-11-03 | 汪东平 | Medicine for treating hepatitis B |
| CN1895619A (en) * | 2005-07-14 | 2007-01-17 | 兰州太宝制药有限公司 | Chinese-medicinal composition for preventing and treating liver disease and its preparation |
| KR20070097234A (en) * | 2006-03-29 | 2007-10-04 | 장병간 | Lactic acid fermentation composition using edible herbs and the preparation method of thereof |
| CN104147270A (en) * | 2014-08-28 | 2014-11-19 | 广西梧州三鹤药业有限公司 | Traditional Chinese medicine for treating acute hepatitis |
Non-Patent Citations (2)
| Title |
|---|
| 余洪波等: "酶法在中药提取中的研究进展", 《中成药》 * |
| 国家药典委员会: "《中华人民共和国药典临床用药须知：2015版. 中药成方制剂卷》", 30 September 2017, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101537060B (en) | Medicine for treating AIDS | |
| CN100488558C (en) | Medicament for treating heart disease and preparation process thereof | |
| CN106215118A (en) | Antineoplastic health preparation and preparation method thereof | |
| CN103142920A (en) | Traditional Chinese medicine composition for treating hepatitis B and preparation method thereof | |
| CN102302574A (en) | Medicament for reinforcing immunity | |
| CN108686168A (en) | A kind of ginseng and astragalus hepar kang tablet | |
| CN107753602A (en) | A kind of Chinese medicine composition for treating leukaemia and preparation method thereof | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN105664053A (en) | Traditional Chinese medicine composition for treating calluses on puncture of internal arteriovenous fistula of maintenance hemodialysis patient | |
| CN105126034A (en) | Pharmaceutical preparation for treating coronary heart disease | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN101375962B (en) | Formulation for activating blood and freeing collateral vessels and preparation method thereof | |
| CN100482268C (en) | Medicinal composition for treating primary hypertension and preparing method of tea agent thereof | |
| CN103520397B (en) | Traditional Chinese medicine for treating pityriasis rubra pilaris | |
| CN102783645B (en) | Health care product for enhancing immunity | |
| CN102302645B (en) | Oral liquid for treating hypertensive cardio-cerebrovascular syndrome | |
| CN105106540A (en) | Medicinal preparation for treating cerebral thrombosis | |
| CN104771558A (en) | Traditional Chinese medicine composition for treating nephritis and preparation method of traditional Chinese medicine composition | |
| CN105343688A (en) | Medicine composition for treating myocardial infarction and application thereof | |
| CN105456933A (en) | Traditional Chinese medicine capable of activating blood to remove stasis and clearing and activating channels and collaterals and preparation method of traditional Chinese medicine | |
| CN104689205A (en) | Traditional Chinese preparation for treating insomnia and dreamful sleep and preparation method thereof | |
| CN104984060A (en) | Traditional Chinese medicament for treating coronary heart disease | |
| CN112245551A (en) | Pure traditional Chinese medicine transdermal liniment for treating liver diseases and preparation method thereof | |
| CN104906265A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN111686207A (en) | Dendrobium devonianum compound preparation and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181023 |